Nektar Therapeutics (NKTR) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Nektar Therapeutics.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.217 We figured that out in our atopic dermatitis program, the 00:00:05.217 -- 00:00:10.563 ideal maintenance dosing after a 16 or 24 week induction 00:00:10.563 -- 00:00:14.827 period should be one month and three months. 00:00:14.827 -- 00:00:20.093 In terms of alopecia areata, after 52 weeks of treatment, we don't 00:00:20.093 -- 00:00:23.917 yet know what the maintenance dosing should be. 00:00:23.917 -- 00:00:28.892 And so for that off treatment, data that we're going to have at the end of this year, 00:00:28.892 -- 00:00:34.058 it's going to be highly informative to us to understand how we should continue 00:00:34.058 -- 00:00:39.464 to dose patients in the alopecia areata program after 52 weeks 00:00:39.464 -- 00:00:44.489 of treatment given 24 micrograms per kilogram every two weeks. 00:00:44.489 -- 00:00:47.330 In terms of 00:00:47.833 -- 00:00:51.537 the data from the RESOLVE-AD 00:00:51.537 -- 00:00:57.482 study, you're absolutely right. We'll continue to follow the durability of 00:00:57.482 -- 00:01:02.308 those patients' responses and those patients who achieved an EZ75, 00:01:02.308 -- 00:01:04.050 an EZ90, 00:01:04.050 -- 00:01:06.894 an IgA0 00:01:06.894 -- 00:01:12.501 and 1, and we'll continue to look at the durability of those responses. 00:01:12.501 -- 00:01:17.847 As we saw with Q monthly dosing and Q 00:01:17.847 -- 00:01:22.933 three-month dosing, we had exceptional durability, and we also saw 00:01:22.933 -- 00:01:28.259 deepening of responses. Now, with the off-treatment, we'll be able to 00:01:28.259 -- 00:01:33.426 determine, you know, are patients able to maintain those easy 00:01:33.426 -- 00:01:38.872 100 responses, the 30% of patients that achieved that, and the IgA 00:01:38.872 -- 00:01:43.899 zero and o...